Taylor Frigon Capital Management Lowers stake in IDEXX Laboratories (IDXX)

IDEXX Laboratories (IDXX) : Taylor Frigon Capital Management reduced its stake in IDEXX Laboratories by 2.58% during the most recent quarter end. The investment management company now holds a total of 18,818 shares of IDEXX Laboratories which is valued at $2,031,779 after selling 499 shares in IDEXX Laboratories , the firm said in a disclosure report filed with the SEC on Aug 3, 2016.IDEXX Laboratories makes up approximately 2.04% of Taylor Frigon Capital Management’s portfolio.

Other Hedge Funds, Including , Harel Insurance Investments Financial Services Ltd. sold out all of its stake in IDXX during the most recent quarter. The investment firm sold 95 shares of IDXX which is valued $10,257.Ngam Advisors reduced its stake in IDXX by selling 11,286 shares or 46.37% in the most recent quarter. The Hedge Fund company now holds 13,052 shares of IDXX which is valued at $1,409,224. IDEXX Laboratories makes up approx 0.02% of Ngam Advisors’s portfolio. Smith Asset Management Group Lp added IDXX to its portfolio by purchasing 134,260 company shares during the most recent quarter which is valued at $12,455,300. IDEXX Laboratories makes up approx 0.36% of Smith Asset Management Group Lp’s portfolio. Nn Investment Partners Holdings N.v. added IDXX to its portfolio by purchasing 800 company shares during the most recent quarter which is valued at $74,920.

IDEXX Laboratories closed down -0.43 points or -0.39% at $108.62 with 5,04,653 shares getting traded on Monday. Post opening the session at $108.8, the shares hit an intraday low of $108.27 and an intraday high of $109.365 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, IDEXX Laboratories reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $466.56 million for the quarter, compared to analysts expectations of $445.57 million. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.

Many Wall Street Analysts have commented on IDEXX Laboratories. IDEXX Laboratories was Upgraded by Northcoast to ” Neutral” on Aug 3, 2016. Company shares were Reiterated by Canaccord Genuity on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 98 from a previous price target of $90 .

IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

IDEXX Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on IDEXX Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.